comparemela.com

Latest Breaking News On - கார்ல் தாமஸ் - Page 22 : comparemela.com

INTERVIEW: After 25 Years In The Industry, Donell Jones Is Where He Wants To Be

My Heart in 1996 and 25 year later, the singer-songwriter is still in his bag. Having the opposite of a sophomore slump, his second album Where I Wanna Be and its Billboard charting title track catapulted Jones to critical success and fame. Fast forward to 2021 and you have a seasoned veteran who just released his seventh album. Released in December of 2020, seven years after his previous album, 100% Free is a project that reflects his evolution not only as an artist, but as a man. A quarter of a century is plenty of time for growth and that is exactly what Jones did. As a husband, father of six, and owner of his own record label, the Chicago native’s current life and music reflect the level of maturity he has reached. 

How Nottingham suburb plagued by drug deals has cleaned up its act

How Nottingham suburb plagued by drug deals has cleaned up its act A new CCTV 4G camera is making people feel safer 16:43, 14 MAR 2021 Updated A view of the alleyway off Oxbow Close in The Meadows, Nottingham. (Image: Joseph Raynor/ Nottingham Post) Never miss another Nottinghamshire story by signing up to our free email updatesInvalid EmailSomething went wrong, please try again later. Subscribe When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplains more about how we use your data, and your rights. You can unsubscribe at any time.

Quantum Leap Healthcare Collaborative Concludes Apremilast Not Likely to Reduce Time to Recovery or Mortality in Critically Ill Patients in I-SPY COVID Trial

Share this article Share this article SAN FRANCISCO, March 12, 2021 /PRNewswire/  Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility. Apremilast was chosen for testing in the I-SPY COVID Trial because it is a phosphodiesterase-4 (PDE4) inhibitor hypothesized to blunt the cytokine storm that accompanies critical illness associated with COVID-19. The I-SPY COVID Trial is a phase II, open label, adaptive platform trial being conducted in critically ill COVID-19 patients who are receiving high flow oxygen or mechanical ventilation. The trial was designed to rapidly screen agents to find those with the best chance of reducing time to recovery (defined as reduction in oxygen demand) by approximately 50% and reducing risk of death. The I-SPY COVID Trial identified the initial agents for the study through a unique partnership with the COVID R&D Alliance, and apremilast was t

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.